

REPORT ID AF-2026-464000	VERIFICATION CODE M7WS-6JTR	CLIENT China Peptide Source	STATUS ACTIVE
PRODUCT Orforglipron 6 mg Tablets	BATCH / LOT ORFO-08F1	SAMPLE RECEIVED Jul 28, 2026	ANALYSIS DATE Jul 30, 2026

CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Purity	RP-HPLC	99.75%	≥99.00%	Conforms
Identity	LC-MS	882.4 Da	882.4 ± 2 Da	Conforms
Unit Content	Gravimetric	6.024 mg	6 mg Target	Conforms

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.425 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.070 ppm	< 0.1 ppm	Pass

ADDITIONAL ANALYTICAL RESULTS

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Appearance	Visual Inspection	Conforms	Product specification	Conforms
Disintegration	USP	6 min	≤ 30 min	Pass
Water Content	Karl Fischer	0.30%	≤ 1.0%	Pass
Related Substances	HPLC (Related Substances)	< 0.10%	≤ 1.0%	Pass
Residual Solvents	Headspace GC	< 10 ppm	≤ 5000 ppm	Pass

METHOD & SAMPLE SUMMARY

PRIMARY METHOD RP-HPLC	MATRIX Tablet	SAMPLE SIZE 6 mg
METHOD REFERENCE AF-TABLET-QC-01	OVERALL DISPOSITION CONFORMS	

VERIFICATION

M7WS-6JTR

<https://analyticalformulations.com/verify/M7WS-6JTR>

Lab ID: AFL-001 · FormuVerify™



Scan to verify certificate